Related Experiment Video
Updated: Jul 10, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Immunosuppressive agents for myasthenia gravis.
I K Hart1, S Sathasivam, T Sharshar
1Walton Centre for Neurology and Neurosurgery, University Division of Neuroscience, Lower Lane, Liverpool, UK, L9 7LJ. i.k.hart@liverpool.ac.uk
The Cochrane Database of Systematic Reviews
|October 19, 2007
Summary
Limited evidence suggests ciclosporin and cyclophosphamide improve generalized myasthenia gravis (MG). Other immunosuppressants like azathioprine, mycophenolate mofetil, and tacrolimus showed no significant benefit in small trials. Larger studies are needed.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- The efficacy of various immunosuppressants for myasthenia gravis (MG) remains unclear.
- Understanding optimal treatment strategies is crucial for managing this autoimmune disorder.
Purpose of the Study:
- To assess the efficacy of different immunosuppressant drugs in patients with myasthenia gravis.
- To provide evidence-based insights into the benefits of various immunosuppressive agents for MG management.
Main Methods:
- Systematic review and meta-analysis of randomized and quasi-randomized controlled trials.
- Searched multiple databases (Cochrane, MEDLINE, EMBASE) and bibliographies for relevant studies published up to July 2007.
- Included trials involving any age, type, or severity of MG, assessing various immunosuppressive interventions and outcomes like clinical improvement and adverse events.
Main Results:
- Ciclosporin demonstrated significant improvement compared to placebo in MG patients, both as monotherapy and with corticosteroids (relative rate of improvement 2.44).
- Cyclophosphamide showed statistical efficacy over placebo in corticosteroid-dependent patients at 12 months.
- Azathioprine, mycophenolate mofetil, and tacrolimus did not show significant benefits over placebo or standard treatments in the included trials, often due to limited data and small sample sizes.
Conclusions:
- Limited evidence from small randomized controlled trials (RCTs) indicates that ciclosporin and cyclophosphamide significantly improve generalized myasthenia gravis.
- Current evidence does not support the use of azathioprine, mycophenolate mofetil, or tacrolimus for significant benefit in MG based on available RCT data.
- Larger, well-designed, and longer-term trials are necessary to definitively establish the efficacy and safety of various immunosuppressants in myasthenia gravis management.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...